200 likes | 328 Views
IP Office and Promising Biotechnologies. Introduction. Chad Hardaway, P.E., MBA, JD Senior Licensing Associate Intellectual Property Office University of South Carolina Research Foundation Life and Physical Sciences. USC Future Keys to Success. Research Focus. New Faculty.
E N D
Introduction Chad Hardaway, P.E., MBA, JD Senior Licensing Associate Intellectual Property Office University of South Carolina Research Foundation Life and Physical Sciences
USC Future Keys to Success Research Focus New Faculty Strategic Partnerships New Facilities Enhanced Academic Reputation Enhanced Economic Development
FocusCurrent Research Themes Biomedical Sciences Nanotechnology Environmental Research NextEnergy
Brain Imaging $5 million USC/MUSC Regenerative Medicine $6 million MUSC/Clemson/USC Translational Cancer Therapeutics $5 million MUSC/USC Drug Discovery in Cancer $5 million MUSC/USC Vision Science $4.5 million MUSC/USC Research Centers of Economic Excellence Funded Proposals
Horizon Center Plans University Private
USC – Licensing Approaches %%%% $$$$ USC has done deals at both extremes and at all points in between! Straight Equity Straight Buy-out
Featured Technologies M3A Novel Antibiotic Compound Novel Hypertension Compound PLEOF Copolymer Networks as a Bioresorbable Scaffold for Tissue Regeneration Fluorescent Bioconjugation Hernia repair with novel collagen scaffolds Additional Technologies PAD Inhibitors for treatment of Rheumatoid Arthritis Novel Methoxyestradiol Compounds Novel Resuscitative Fluid for Trauma Patients Cold Sterilization Promising Biotechnologies
M3A Novel Antibiotic Compound OVERVIEW Novel Antibiotic Broad spectrum activity Effective against resistant strains Drug resistance is an ongoing problem STATUS DEVELOPMENT NEEDS Isolate & identify compound(s) Develop production process Additional efficacy testing Preclinical safety testing Culture process developed Initial efficacy & safety data US patent issued
Novel Hypertension Compound OVERVIEW Effective for treatment of cardio conditions and spasmodic asthma Dual Action – L-type Ca2+ antagonist cAMP PDE inhibitor Slows rate without blocking antrioventricular conduction STATUS DEVELOPMENT NEEDS Additional efficacy testing Preclinical safety testing Development to market In vivo testing on carotid arterial blood pressure Preliminary in vivo safety data In vitro testing on cardio and smooth muscle effects US patent pending
PLEOF Copolymer Networks as a Bioresorbable Scaffold for Tissue Regeneration OVERVIEW Spinal Fracture 40 M affected by arthritis in US. 1 M patients undergo surgery for osteoarthritis of knee, hip, shoulder, and spine every year. These PLEOF compounds can be used to repair/ replace damaged bone, cartilage, etc. Injection of Composite STATUS DEVELOPMENT NEEDS • Additional efficacy testing • Preclinical safety testing • Short FDA approval route as device • Develop to Market Preliminary in vitro and in vivo data collected Can be produced in large quantities US Patent Pending
Fluorescent Bioconjugation OVERVIEW Process for linking nanoparticles Fluorescent signal created with linkage Wide applications including pharmaceuticals, diagnostics, and various other nanotech uses DEVELOPMENT STATUS DEVELOPMENT NEED Lab testing complete Variety of reactions tested Hundreds of novel dyes made Patent pending Target market analysis Financial & business analysis Validation of target applications
Hernia repair with novel collagen scaffolds OVERVIEW Before Currently there is no wide acceptance of Engineered soft tissues and no gold standard for repair of ventral hernias. This technology offers a tissue engineered repair system that can rapidly vascularize to repair ventral hernial defects as well as other defects. After DEVELOPMENT NEEDS STATUS Repaired over 30 rat ventral hernias Demonstrated the control release technology causes rapid neovascularization Demonstrated differentiated skeletal muscle within the repair site. • Establish the technology to obtain full thickness muscular repair • Transfer technology to large animal studies • Initiate the FDA approval process.
IP Office Contact Information Lisa Rooney, JD, Director 803-777-6450 LRooney@sc.edu Chad Hardaway, P.E., MBA., JD Senior Licensing Associate 803-777-4031 Hardaway@gwm.sc.edu USC Research Foundation Intellectual Property Office 901 Sumter Street, Suite 514 Columbia, SC 29208 Web Site http://ip.research.sc.edu